TOKYO (Reuters): Shionogi & Co has sold the development and marketing rights for a Covid-19 treatment to California-based biotech BioAge Labs Inc, the Japanese drugmaker said on Tuesday (Jan 26).
Shionogi discovered the drug, known as BGE-175, and developed it to treat allergic rhinitis.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
